Standard BioTools Stock

Standard BioTools FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Standard BioTools (LAB) as of Jul 22, 2026 is 82.10 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 61.77 % — a change of 32.91% (higher).

FCF Conversion

82.10 %

YoY

32.91%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Standard BioTools is 2026 82.10 % . FCF Conversion Rate (FCF/EBITDA) of Standard BioTools was 2025 61.77 % . It decreases by 32.91% higher compared to the previous year.
Access this data via the Eulerpool API

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

FCF Conversion Rate (FCF/EBITDA) of Standard BioTools is 82.10 % in 2026.

Access this data via the Eulerpool API

Cash Flow — Standard BioTools

All Key Metrics — Standard BioTools